Literature DB >> 31868113

A cocktail of betulinic acid, parthenolide, honokiol and ginsenoside Rh2 in liposome systems for lung cancer treatment.

Xin Jin1, Qing Yang1, Ning Cai1, Zhenhai Zhang2.   

Abstract

Aim: Lung cancer has a very high incidence rate, and thus, there is an urgent need for novel and effective therapies. Materials & methods: In this study, we proposed a potential treatment option by combining four natural products in liposome systems.
Results: In vitro studies indicated that the combination of betulinic acid, parthenolide, honokiol and ginsenoside Rh2 exhibited a synergistic action. When these four natural products were loaded into liposome systems, we observed an increased effect. The relative action was also observed in vivo. The cisplatin group presented obvious kidney damage, whereas both cocktail therapy and cocktail liposome therapy were safer.
Conclusion: Therefore, we propose cocktail liposome systems may provide a more efficient and safer treatment for lung cancer.

Entities:  

Keywords:  betulinic acid; cocktail therapy; ginsenoside Rh2; honokiol; liposomes; lung cancer; natural products; parthenolide

Mesh:

Substances:

Year:  2020        PMID: 31868113     DOI: 10.2217/nnm-2018-0479

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  11 in total

Review 1.  Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation.

Authors:  Wamidh H Talib; Izzeddin Alsalahat; Safa Daoud; Reem Fawaz Abutayeh; Asma Ismail Mahmod
Journal:  Molecules       Date:  2020-11-14       Impact factor: 4.411

2.  Assessment of a New Ginsenoside Rh2 Nanoniosomal Formulation for Enhanced Antitumor Efficacy on Prostate Cancer: An in vitro Study.

Authors:  Hadi Zare-Zardini; Ashraf Alemi; Asghar Taheri-Kafrani; Seyed Ahmad Hosseini; Hossein Soltaninejad; Amir Ali Hamidieh; Mojtaba Haghi Karamallah; Majid Farrokhifar; Mohammad Farrokhifar
Journal:  Drug Des Devel Ther       Date:  2020-08-13       Impact factor: 4.162

3.  Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.

Authors:  Yulin Ren; A Douglas Kinghorn
Journal:  J Med Chem       Date:  2020-12-08       Impact factor: 7.446

Review 4.  Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery.

Authors:  Sepideh Mirzaei; Ali Zarrabi; Farid Hashemi; Amirhossein Zabolian; Hossein Saleki; Negar Azami; Soodeh Hamzehlou; Mahdi Vasheghani Farahani; Kiavash Hushmandi; Milad Ashrafizadeh; Haroon Khan; Alan Prem Kumar
Journal:  Antioxidants (Basel)       Date:  2021-02-26

5.  Ginsenoside Rh2 reduces m6A RNA methylation in cancer via the KIF26B-SRF positive feedback loop.

Authors:  Chunmei Hu; Linhan Yang; Yi Wang; Shijie Zhou; Jing Luo; Yi Gu
Journal:  J Ginseng Res       Date:  2021-05-25       Impact factor: 6.060

Review 6.  Ginsenosides emerging as both bifunctional drugs and nanocarriers for enhanced antitumor therapies.

Authors:  Hong Wang; Yu Zheng; Qiang Sun; Zhen Zhang; Mengnan Zhao; Cheng Peng; Sanjun Shi
Journal:  J Nanobiotechnology       Date:  2021-10-15       Impact factor: 10.435

Review 7.  The Optimized Delivery of Triterpenes by Liposomal Nanoformulations: Overcoming the Challenges.

Authors:  Andreea Milan; Alexandra Mioc; Alexandra Prodea; Marius Mioc; Roxana Buzatu; Roxana Ghiulai; Roxana Racoviceanu; Florina Caruntu; Codruţa Şoica
Journal:  Int J Mol Sci       Date:  2022-01-20       Impact factor: 5.923

Review 8.  Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy.

Authors:  Albert Yu; Xiaoyong Dai; Zixian Wang; Huaqing Chen; Bing Guo; Laiqiang Huang
Journal:  Biosensors (Basel)       Date:  2022-02-10

Review 9.  The Emerging Potential of Parthenolide Nanoformulations in Tumor Therapy.

Authors:  Tao An; Huanhuan Yin; Yanting Lu; Feng Liu
Journal:  Drug Des Devel Ther       Date:  2022-04-29       Impact factor: 4.319

Review 10.  The Effect of Terpenoid Natural Chinese Medicine Molecular Compound on Lung Cancer Treatment.

Authors:  Heng Sun; Lijia Zhang; Bowen Sui; Yu Li; Jun Yan; Peng Wang; Ye Wang; Songjiang Liu
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-16       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.